ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following two investor conferences in May:
-- The Deutsche Bank Securities 36th Annual Health Care Conference on May 2, 2011 at 9:20 AM EDT. The conference is being held at the Intercontinental Hotel in Boston.
-- 10th Annual JMP Securities Research Conference on May 10, 2011 at 3:00 PM PDT. The conference is being held at the Ritz Carlton Hotel in San Francisco.
Inhibitex, Inc., is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes FV-100, a nucleoside inhibitor in Phase 2 for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
KEYWORDS: United States North America California Georgia Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Pharmaceutical